Deciphering therapy resistance mechanisms in KRAS-mutant lung cancer.
Investigating the molecular pathways that contribute to therapy resistance in KRAS-mutant lung cancer to identify potential therapeutic targets.
Integrative molecular characterization and personalized modelling of pleural mesothelioma (PM).
Combining molecular profiling and personalized models to better understand PM and develop tailored treatment approaches.
Ferroptosis as a therapeutic avenue for lung cancer and PM.
Exploring the potential of ferroptosis, a form of regulated cell death, as a novel strategy to target lung cancer and malignant pleural mesothelioma.
